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Few large, international series of
enteropathy-associated T-cell lymphoma
(EATL) have been reported. We studied
a cohort of 62 patients with EATL among
1153 patients with peripheral T-cell or
natural killer (NK)–cell lymphoma from
22 centers worldwide. The diagnosis
was made by a consensus panel of
4 expert hematopathologists using
World Health Organization (WHO) crite-
ria. Clinical correlations and survival
analyses were performed. EATL com-
prised 5.4% of all lymphomas in the
study and was most common in Europe
(9.1%), followed by North America (5.8%)
and Asia (1.9%). EATL type 1 was more
common (66%) than type 2 (34%), and
was especially frequent in Europe (79%).
A clinical diagnosis of celiac sprue was
made in 32.2% of the patients and was
associated with both EATL type 1 and
type 2. The median overall survival was
only 10 months, and the median failure-
free survival was only 6 months. The
International Prognostic Index (IPI) was
not as good a predictor of survival as
the Prognostic Index for Peripheral
T-Cell Lymphoma (PIT). Clinical sprue
predicted for adverse survival indepen-
dently of the PIT. Neither EATL subtype
nor other biologic parameters accu-
rately predicted survival. Our study con-
firms the poor prognosis of patients
with EATL and the need for improved
treatment options. (Blood. 2011;118(1):
148-155)
Introduction
Enteropathy-associated T-cell lymphoma (EATL) is a primary intestinal
lymphoma that is often, but not always, associated with celiac sprue.1-9 It
is a rare disease in most parts of the world, with an annual incidence rate
of 0.5-1 per million.10,11 Because EATL is rare, large systematic studies
of this lymphoma are scarce. EATL occurs predominantly in middle-
aged men and is localized primarily in the small bowel. This lymphoma
is strongly associated with celiac sprue, with a variable time lapse of a
few months to several decades between the diagnosis of celiac sprue and
the onset of lymphoma.10,12 EATL has a poor prognosis due to treatment
resistance and sepsis or perforation of the bowel at diagnosis or during
the course of treatment.
Recent studies indicate that EATL consists of 2 diseases that are
morphologically and genetically distinct and differ with respect to
their frequency of association with celiac sprue.13-20 The first type
of EATL (type 1) is characterized genetically by chromosome
9q31.3 gain or 16q12.1 deletion and is strongly associated with
celiac sprue and the HLA-DQ2 haplotype. Interestingly, these
lymphomas frequently have a large-cell or pleomorphic cytology
and may express CD30. In contrast, EATL type 2 is characterized
by chromosome 8q24 gain and, less commonly, by 1q and 5q gains.
EATL type 2 is less frequently associated with celiac sprue and the
HLA-DQ2 haplotype13,16 and is characterized by monomorphic
cytology with frequent expression of CD56.
In an effort to assess the clinical applicability of the World Health
Organization (WHO) classification of peripheral T- and natural killer
(NK)–cell lymphomas, and to evaluate the efficacy of the therapies used,
a large international study was conducted.21 The clinical and pathologic
findings of the EATL cases included in the study are reported here.
Methods
Case selection and collection of clinical data
The cases in this study are part of the International Peripheral T-Cell
Lymphoma Project. The study was approved by the institutional review
boards of all participating centers, and an overview of the entire project has
been published previously by Vose et al.21 Briefly, the cases were collected
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from 22 centers in North America, Europe, and Asia. All patients were
adults ( 19 years) with a primary diagnosis of peripheral T-cell lymphoma
(PTCL) or NK-cell lymphoma made between January 1, 1990 and
December 31, 2002. The clinical features of the patients were required for
all cases and data were collected as described by Vose et al.21 Cases of
mycosis fungoides and Se´zary syndrome were excluded.
Histology review
Local pathologists submitted representative diagnostic materials, including
a paraffin-embedded tissue block, to a regional center for more detailed and
standardized immunophenotyping and review. The immunophenotyping
consisted of stains for CD20, CD3, CD4, CD5, CD8, CD30, CD56,
TCR-beta, TIA-1, and Ki67. In situ hybridization for EBV was also
performed. Clonality analyses or FISH studies for defined genetic aberra-
tions were performed as necessary to classify the cases according to the
2001 WHO classification.22 Panels of 4 expert hematopathologists drawn
from the contributing local sites and regional centers traveled to the
regional centers to review the cases. The composition of the panels differed
at the various regional centers. A consensus diagnosis was rendered when at
least 3 experts in the respective panel agreed on the diagnosis.
In total, 1314 cases were reviewed and a diagnosis of PTCL or
NK-cell lymphoma was confirmed in 1153 cases. A diagnosis of
enteropathy-type TCL was made when the patient presented with a
tumor in the intestine composed of EBV-negative lymphoma cells with a
mature T-cell immunophenotype. Cases diagnosed as enteropathy-type
TCL were renamed EATL and were subsequently further classified
by 2 of the hematopathologists (D.D.W. and J.D.) into 2 subtypes
according to the 2008 WHO classification.23 This subdivision was based
on histologic analysis and did not take into account clinical evidence of
celiac sprue. The first subtype is called EATL type 1 for the purposes of
this study, although this terminology is not used in the WHO classifica-
tion. EATL type 1 shows a variable histology consisting of either a
monomorphic infiltrate of medium-sized to large lymphoma cells with
irregular nuclear contours and a variable amount of cytoplasm or large
anaplastic lymphoma cells. EATL type 1 may also show a marked
polymorphism with variable numbers of eosinophils, histiocytes, small
lymphocytes, and plasma cells. For EATL type 1, histologic features of
celiac sprue in the adjacent mucosa not infiltrated with lymphoma were
investigated. However, adjacent noninfiltrated mucosa was not present
in all cases. Celiac sprue was diagnosed when increased numbers of
intra-epithelial lymphocytes ( 30 of 100 enterocytes) along with either
crypt hyperplasia or villus atrophy was noted, as reviewed by Green et
al.24 EATL type 2 is characterized by a monomorphic infiltrate of small-
to medium-sized lymphoid cells with round, hyperchromatic nuclei
having a stippled chromatin pattern. We also investigated whether
intra-epithelial infiltration of the mucosa by lymphoma cells was
present.
Statistical analysis
Treatment outcomes were measured by failure-free survival (FFS) and
overall survival (OS). FFS was defined as the time from initial diagnosis to
the first occurrence of progression, relapse after response, or death from any
cause. Follow-up of patients not experiencing one of these events was
censored at the date of last contact. OS was measured from the time of
initial diagnosis to death from any cause, with surviving patient follow-up
censored at the last contact date. Estimates of FFS and OS were determined
using the method of Kaplan and Meier,25 and time-to-event distributions
were compared using the log-rank test.26 The Cox proportional hazards
regression model was used to test whether pathologic or clinical features or
a history of celiac sprue predicted for FFS or OS. This was done after
controlling for clinical prognostic indices such as the International Prognos-
tic Index (IPI)27 and the Prognostic Index for PTCL, unspecified (PIT),28
respectively.
Figure 1. Typical EATL type 1 histology from one of
the cases in the study. (A) The cells are large with
irregularly shaped or angulated nuclei and a variable
amount of cytoplasm (magnification, 250). (B) The cells
in this case expressed CD30 (magnification, 250). The
mucosa adjacent to the tumor had shortened villi (C;
magnification, 100) and “top-heavy” intra-epithelial infil-
tration by T cells (D; CD3 staining, magnification, 100).
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Results
Histology
Of the 68 cases in the study cohort in which a local diagnosis of
EATL was submitted, only 62 cases were considered to be EATL
after review. Three cases were diagnosed as PTCL, unspecified;
1 as anaplastic large-cell lymphoma; and 2 as extranodal NK-/T-
cell lymphoma, nasal type. In total, 5.4% of the cases (62 of 1153)
were considered to be EATL after review, thus representing the
seventh largest category of PTCL in the cohort. The expert
agreement with the consensus diagnosis of EATL was 79%.
Significant regional differences were noted in the relative fre-
quency of EATL, which represented 1.9%, 5.8%, and 9.1% of
PTCL in Asia, North America, and Europe, respectively (P .0001).
EATL type 1 constituted 66% (38 of 58) and EATL type
2 constituted 34% (20 of 58) of the cases available for subclassifi-
cation. In 4 cases, the materials were no longer available for
subclassification at the time this analysis was performed. The
typical histology of EATL type 1 and type 2 is illustrated in Figures
1 and 2, respectively, and the immunophenotypes are given in Table
1. As expected, EATL type 2 expressed CD8 and CD56 more often
than EATL type 1. EATL type 1 was more common than type 2 in
Europe, whereas the latter was more common in Asia. EATL types
1 and 2 were equally frequent in North America (Figure 3). An
association with a clinical history of celiac sprue was noted for both
EATL type 1 and type 2, representing 16 of 33 cases and 4 of
20 cases, respectively (Table 2). Histological features of celiac
sprue were seen in 11 of 28 cases of EATL type 1 in which the
mucosa adjacent to the tumor could be investigated. European
cases were most frequently associated with celiac sprue when the
clinical history and histologic features were combined (Figure 3).
All 13 cases of EATL type 2 in which adjacent mucosa was
included in the biopsy showed intra-epithelial lymphoma with or
without villous atrophy. This feature precluded histological evalua-
tion for celiac disease in EATL type 2.
Clinical data
The clinical features of the cases are given in Table 3. EATL
occurred most frequently in the sixth decade, with an almost equal
distribution among the sexes. Abdominal pain, fatigue, and an-
orexia were the most frequent symptoms. Approximately one-fifth
of the patients presented with signs of infection, but there was no
clinical information on perforation of the bowel available in the
study. Whereas the clinical disease stage was usually advanced at
diagnosis, bone marrow involvement was a rare occurrence. Except
Figure 2. Typical EATL type 2 histology from one of
the cases in the study. (A) The lymphoma consists of
monotonous, medium-sized cells with round nuclei hav-
ing a stippled chromatin pattern (magnification, 250).
(B) The cells express CD56 (magnification, 250). The
mucosa adjacent to the lymphoma, shows villous atrophy
(C; magnification, 100) and intra-epithelial infiltration by
lymphoma cells (D; CD56 staining, magnification, 400).
Table 1. Immunophenotype of EATL
EATL type 1 EATL type 2 P
CD3e 89% 95% NS
CD2 43% 53% NS
CD5 17% 6% NS
CD4 11% 5%* NS
CD8 43% 63% NS
CD30 37.5% 12.5%* .09
CD56 30% 73% .01
TIA-1 81% 87.5% NS
EBV (EBER-ISH) 10%* 12%* NS
NS indicates not significant.
*Only a subpopulation of likely reactive cells were positive.
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for tumor size at diagnosis, no significant clinical differences were
noted between EATL types 1 and 2, including a clinical history of
celiac sprue (P  .13). A tumor of 5 cm at diagnosis was
reported in 11 of 24 patients with EATL type 1 versus 15 of 18 with
EATL type 2 (P  .02). There was no correlation between the
tumor size at diagnosis and a history of celiac sprue. As expected,
the small intestine was the most commonly involved site at
diagnosis (90%), followed by the large intestine (16%), with
frequent involvement of mesenteric (35%) and para-aortic or iliac
lymph nodes (11%; Table 4). In one case, EATL type 1 involved the
stomach but not the small intestine. In 3 cases, EATL involved the
large intestine without involving the small intestine; 2 of these
cases were EATL type 2 but the slides of the third case were not
available for subtype review. The small and large intestine were
simultaneously involved in 7 cases, of which 3 were EATL type
1 and 4 were type 2.
Treatment was administered in 56 of the patients, whereas no
treatment could be given in 5 patients because of their general
condition. In one patient, no information on treatment could be
retrieved. Initial treatment in 52 patients consisted of combination
chemotherapy containing anthracycline; of these patients, 27 received
CHOP, 8 CHOP-like, 3 MACOP-B, 2 ACVB, 2 CEOP, and 2 CHO
chemotherapy. The remaining 8 patients received a diverse combination
of chemotherapy regimens. Complete response, partial response, or no
response was observed in 40%, 16%, and 38% of the patients,
respectively, whereas no data were available for the other patients. None
of the patients received consolidative autologous stem cell transplanta-
tion in first remission. No data with respect to salvage therapy was
recorded for this study.
Survival analysis
Survival data were available for 61 of the 62 patients. The median
follow-up was 10.5 months. The median OS was only 10 months
and the FFS was only 6 months. The 5-year OS was 20%, but the
5-year FFS was only 4%. In univariate analysis, there was a
significantly decreased FFS in cases with a history of celiac sprue
compared with those without sprue documented in the clinical
records (P  .02); however, there were no significant differences in
OS between these 2 groups (P  .17). When survival with respect
to a history of celiac sprue was analyzed only for EATL type 1,
similar results were obtained; a lower FFS was seen in the patients
with celiac sprue (P  .03), but no significant difference in OS was
noted (P  .18; Figure 4A). The survival analysis for EATL type
1 was repeated to include cases with either a clinical history or
histological evidence of celiac disease (Figure 4B). Interestingly, a
significantly decreased OS was observed for patients with celiac
sprue (P  .039), whereas only a borderline decrease in FFS was
seen (P  .069). The number of EATL type 2 cases with a clinical
history of celiac sprue was too small (n 4) to perform survival
analysis. Disease stage (stage III or IV) and age 60 years did not
predict for OS or FFS (P  .95 and P  .73, P  .34 and P  .72,
respectively), but a large tumor mass ( 5 cm) at diagnosis (Figure
5A), a nonambulatory performance status, an elevated serum LDH
level, and increased C-reactive protein (CRP) were adverse predic-
tors of survival (P values for OS are P  .018, P  .005, P  .008,
and P  .003 for OS, and P  .008, P  .001, P  .001, and
P  .01 for FFS, respectively). The use of anthracycline-
containing chemotherapy improved the OS and FFS compared with
other therapies or no therapy (P  .001 and P  .007, respec-
tively), although the number of patients not receiving an anthracy-
cline-containing regimen was small (n 9) compared with those
receiving such a regimen (n 51; Figure 5B). No analysis of
second-line treatment could be performed because this information
was not recorded in the study. The IPI did not stratify patients well
with regard to OS or FFS (P  .13 and P  .34, respectively), but
the PIT was a better predictor of survival (P  .001 and P  .001,
respectively; Figure 6).
In multivariate analysis, only a clinical history of celiac sprue
predicted FFS when controlling for the PIT (P  .03). A history of
celiac sprue did not predict OS (P  .17). A history of celiac sprue
also predicted FFS when only EATL type 1 was considered
(P  .04), but did not predict OS (P  .15). None of the other
clinical features of EATL predicted for OS or FFS when controlling
for the PIT.
Table 2. Association of EATL with celiac sprue
EATL type 1 EATL type 2
Clinical history of celiac sprue 16 of 33 (48%)* 4 of 15 (27%)*
Histological features of celiac sprue 11 of 28 (39%)*
Clinical history or histologic features of
celiac sprue
21 of 35 (60%)*
*Total number of patients with available data or slides to evaluate for celiac sprue.
Figure 3. EATL and celiac sprue. The percentage of EATL cases (dark
area) among all PTCL cases (circle) in the 3 geographic regions is depicted
on top. The number of cases of EATL type 1 (blue columns) and type 2 (red
columns) is also depicted for the different regions. The crossed areas of the
columns represent the number of cases with a clinical history of celiac sprue.
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None of the immunohistochemical markers, including CD8,
CD56, CD30, or TIA1, were predictors of OS (P  .80, P  .49,
P  .16, and P  .55, respectively) or FFS (P  .73, P  .46,
P  .33, and P  .47, respectively) in univariate analysis. When
using several cutoff scores at 10% intervals for the proliferation-
associated marker Ki67, no significant correlation with survival was
found (P .41 for OS and and P .16 for FFS for a 70% cutoff value).
In addition, there were no significant differences in OS (P .28) or FFS
(P .22) between patients with EATL type 1 and type 2.
Discussion
As seen in previously published studies of EATL7,13,29,30 and
corroborated by the present study, it is evident that EATL as defined
by the WHO classification has distinctive histological and clinical
characteristics. This lymphoma usually involves the small intes-
tine, and most patients present with abdominal pain or signs of
intra-abdominal sepsis. The majority of EATL patients have
advanced-stage disease and their prognosis is dismal. The latter
may be explained, at least in part, by frequent perforation of the
bowel and infection related to tumor progression or treatment.
Three previous studies7,29,30 consisting of 30, 31, and 80 patients,
respectively, reported a significant predominance of men affected
by EATL. However, our series of 62 patients, as well as the study of
70 patients by Chott et al,13 showed only a slight predominance of
men. Agreement between the expert hematopathologists and the
consensus diagnosis of EATL was relatively high (79%), indicating
that criteria for the diagnosis of EATL in the WHO classification
are well established. The 2001 WHO classification was used in this
study because the pathology review was done before 2008. The
2001 criteria are similar to those in the 2008 classification, with the
exception of recognition of EATL type 2 in the latter. However,
EATL type 2 would still have been diagnosed as EATL in the 2001
WHO classification.
EATL comprised only 5.4% of all PTCL in our study, which
makes it rather rare, and there were notable regional differences in
its relative frequency. In our study, EATL was 5 times more
frequent in Europe than in Asia, whereas the frequency in North
America was intermediate. These data are interesting but need to be
interpreted with caution in view of the fact that our study was not
population based, but rather institution based, which may lead to a
biased selection of cases. Data from another institution-based study
from Taiwan31 of 600 PTCL cases showed EATL to have a relative
frequency of 8.1%, which is almost as high as we observed in
Europe. Additional studies of this disease in different parts of the
world are needed to clarify this issue.
Previous studies have identified 2 subtypes of EATL.13-20 EATL
type 1 consists of medium-sized to large or pleomorphic cells and
usually develops in the background of celiac sprue. As with celiac
sprue, EATL type 1 is usually associated with the HLA-DQ2 or,
less frequently, with the HLA-DQ8 haplotype. EATL type 1 may
Table 3. Clinical features of the 62 patients with EATL
Feature
Age, y
Median 60 (61)
Range 33-81 (61)
Sex
Male 53% (33)
Female 47% (29)
Stage
IE 10% (6)
IIE 21% (13)
IIIE 5% (3)
IV 64% (39)
B symptoms
No 37% (23)
Yes 63% (39)
Largest mass
 5 cm 37% (17)
 5 cm 63% (29)
Bone marrow involvement
No 97% (60)
Yes 3% (2)
Elevated LDH
No 65% (37)
Yes 35% (20)
Hypercalcemia
No 91% (46)
Yes 9% (3)
Elevated CRP
No 17% (9)
Yes 33% (25)
History of celiac sprue
No 52% (32)
Yes 32% (20)
Symptoms
Abdominal pain 88% (30)
Fatigue 38% (13)
Anorexia 38% (13)
Infection 23% (8)
Adenopathy 15% (5)
Hepatomegaly 6% (2)
Splenomegaly 6% (2)
Pruritus 3% (1)
IPI score
0/1 25% (14)
2 30% (17)
3 32% (18)
4/5 12% (7)
PIT score
0 25% (14)
1 34% (19)
2 32% (18)
3-4 9% (5)
5-yr OS 20% (61)
5-yr FFS 4% (61)
The numbers in parentheses represent the number of patients with the respec-
tive feature or the number of patients analyzed for this parameter.
Table 4. Sites of involvement in 62 patients with EATL
Site %
Small intestine 90
Mesenteric/intra-abdominal LNs 35
Large intestine 16
Para-aortic/iliac LNs 11
Stomach 8
Inguinal/femoral LNs 6
Lung 5
Skin 5
Cervical/supraclavicular LNs 3
Axillary LNs 3
Bone marrow 3
Liver 2
Spleen 2
Mediastinal LNs 2
Intrathoracic LNs 2
Paranasal sinus 2
Other extranodal sites 13
LNs indicates lymph nodes.
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sometimes develop from an in situ lesion associated with celiac
sprue that is refractory to therapy. EATL type 2 consists of
monomorphic small- to medium-sized cells that usually express
CD8 and CD56, and is not strongly associated with either celiac
sprue or with the HLA-DQ2 or HLA-DQ8 haplotypes. A precursor
lesion is not described for this subtype, although an intra-epithelial
component of T cells with an immunophenotype similar to the
tumor cells is frequently observed,23 as confirmed by our study.
The two subtypes of EATL also have different patterns of
genetic aberrations.14-16,18,20 In this international series, EATL type
1 was the most frequent subtype (66%). Previous reports indicate
that EATL type 1 has a high frequency in Western countries,
comprising approximately 80% of cases.13 In contrast, EATL type 2
has been reported to be the predominant subtype in Asia, represent-
ing  90% of cases.18-20 The predominance of EATL type 1 in the
West and type 2 in the East is confirmed by our study, although the
number of cases from the East was low. Celiac sprue is a known
predisposing factor for EATL, and has been reported to be
especially associated with EATL type 1, as reviewed by Van de
Water et al.12 However, our data show that EATL type 2 can also
arise in patients with celiac sprue. This latter association does not
seem to show a regional variation despite the observed differences
in the frequency of EATL (Figure 3). These observations need to be
confirmed by a study consisting of a larger number of well-
documented cases from Asia. Our data also show that patients with
EATL types 1 and 2 do not display significantly different clinical
features, with the exception of larger tumor masses in those with
EATL type 2. In addition, EATL type 1 and type 2 have an equally
poor prognosis, which is in agreement with a previous study.13
Our study showed a significant correlation between a clinical
history of celiac sprue and FFS in EATL that was independent of
the PIT. Such a correlation could not be shown for OS. However,
because celiac sprue is often undiagnosed,32 it was likely underesti-
mated in our series. Celiac sprue is the most common genetic
disease in North America and Europe, affecting 0.5% to 1% of the
population. As many as 90% of cases are undiagnosed because of
the diversity of symptoms with which patients present.32 Therefore,
the association of EATL with celiac sprue is likely to underesti-
mated in most studies. Future studies should include more sensitive
methods for the detection of celiac sprue, such as measurement of
anti-endomysial and anti-tissue transglutaminase antibodies in
addition to endoscopic small bowel biopsy, to determine the true
incidence of celiac sprue among EATL patients and to determine
more accurately its correlation with survival.
A large tumor mass ( 5 cm), nonambulatory performance
status, and elevated serum LDH and CRP levels are risk factors
significantly associated with a worse OS and FFS in EATL. A large
tumor mass often results in complications such as perforation or
infection, and nonambulatory patients may have disease complica-
tions or not be able to receive aggressive therapy. Similarly, a high
Figure 4. Survival of patients with EATL type
1 according to the presence of celiac disease.
(A) Celiac disease as evidenced by review of the clinical
records alone. (B) Celiac disease as evidenced either by
review of the clinical records or review of the histology.
Figure 5. Survival of patients with EATL according to
tumor size (A) and therapy with or without an anthra-
cycline (B).
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serum LDH level is usually a reflection of high tumor burden. CRP
is produced by hepatocytes secondary to inflammatory cytokines
such as IL6, TNF, and IL1 and is a marker of inflammation.
High serum CRP levels may reflect extensive tissue damage,
ulceration, perforation, and secondary inflammation in EATL, and
therefore may explain the adverse prognosis. Interestingly, the IPI27
did not stratify patients well into prognostic subgroups, whereas the
PIT28 was more predictive of survival. This may have been due to
the fact that age, the number of extranodal sites, and tumor stage,
3 of the 5 components of the IPI, are irrelevant for EATL prognosis.
Indeed, our study indicates that tumor size rather than tumor stage
defines the prognosis in EATL. In contrast, the PIT uses only
4 parameters: LDH, age, bone marrow involvement, and perfor-
mance status. Of these, only bone marrow involvement may not be
relevant to prognosis in EATL, because only a few patients (3.2%)
had this feature in our study.
Patients treated with anthracycline-based chemotherapy regi-
mens had better survival rates than those treated with other forms
of therapy (including surgery) or no therapy at all. However, these
results can be explained by the likely possibility that patients not
receiving anthracycline-based chemotherapy either died before any
therapy could be given or shortly after surgery for advanced or
complicated disease. In addition, the number of patients not
receiving anthracycline-based chemotherapy (n 9) was rather
low. It is clear that novel treatment strategies are needed for
patients with EATL. A recent study by Sieniawski et al30 showed
that patients treated with high-dose ifosfamide, etoposide and
epirubicin/methotrexate followed by autologous stem cell transplan-
tation had a significantly improved survival. However, this might
have been due, at least in part, to the selection of patients who
better tolerate this intensive therapy. Nevertheless, high-dose
chemotherapy with stem cell transplantation was well tolerated in
this patient group, and it was estimated that approximately 70% of
all EATL patients may benefit from this therapy.30 In addition, the
early detection of celiac sprue using improved screening methods
and close clinical follow-up would likely result in earlier detection
of EATL and perhaps better survival rates.
It is increasingly clear that celiac disease is also associated with
lymphomas other than EATL, in particular diffuse large B-cell
lymphoma.33-35 However, the latter was not studied in the Interna-
tional Peripheral T-Cell Lymphoma Project.
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